Andere Sprachen Teva Pharmaceutical Industries Limited

Aktien

883035

US8816242098

TEVA

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 18.04.2024			% 5 Tage	% 1. Jan.
12.78 ^USD	-3.03%		-7.86%	+22.41%

17.04.	Alvotech und Teva geben FDA-Zulassung von SELARSDI (Ustekinumab-aekn), Biosimilar zu Stelara (Ustekinumab), bekannt	CI
11.04.	Teva Pharmaceutical Unit gibt bekannt, dass Ajovy zur Vorbeugung von Migräne in China primäre und sekundäre Endpunkte erreicht hat	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17.04.
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17.04.
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.
Teva Pharmaceutical Industries : Immediate Report	16.04.
Teva Pharmaceutical Industries : Immediate Report	16.04.
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	16.04.
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	16.04.
Teva enters into oncology biosimilar licensing agreement	16.04.
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	11.04.
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	11.04.
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	11.04.
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	09.04.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024	08.04.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	06.04.
TEVA Successfully Opposed Trademark AZILIDE	05.04.
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	04.04.
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate	04.04.
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	03.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Teva Pharmaceutical Industries Limited: Muss weiter Federn lassen

Am 01. Februar 2024 um 11:04 Uhr

Teva CEO über das zweite Quartal und einen möglichen DOJ-Vergleich

Am 02. August 2023 um 21:19 Uhr